Sagent, Actavis To Develop, Market Specialty Injectable Medications For US
Under the agreement, Actavis will develop, obtain US FDA approval and supply the products, which Sagent will market in the US. Jeffrey Yordon, CEO, founder and chairman of
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
The 8 non-antibiotic oral formulations licensed to Alvogen under the agreement comprise products in the high growth therapeutic segments of CNS and Osteoporosis among others. Under this agreement,